{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:46:45Z","timestamp":1792234005098,"version":"4.4.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.104545","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T14:41:34Z","timestamp":1744296094000},"page":"104545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"J.","family":"Rodon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.K.","family":"Mangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0333","authenticated-orcid":false,"given":"E.","family":"Garrett-Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-3071","authenticated-orcid":false,"given":"T.L.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-0131","authenticated-orcid":false,"given":"E.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.P.","family":"Kalemkerian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Hinshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4369","authenticated-orcid":false,"given":"A.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0419","authenticated-orcid":false,"given":"G.N.","family":"Grantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":false,"given":"S.","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-4303","authenticated-orcid":false,"given":"R.L.","family":"Schilsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2025.104545_bib1","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1093\/nar\/gkw282","article-title":"Discovering and understanding oncogenic gene fusions through data intensive computational approaches","volume":"44","author":"Latysheva","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104545_bib2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104545_bib3","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1200\/JCO.2023.41.16_suppl.3132","article-title":"NRG1 fusions in solid tumors","volume":"41","author":"Gupta","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104545_bib4","series-title":"Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects","first-page":"561","article-title":"Neuregulin-1 and neurovascular protection","author":"Wu","year":"2015"},{"key":"10.1016\/j.esmoop.2025.104545_bib5","doi-asserted-by":"crossref","first-page":"S756","DOI":"10.1016\/j.annonc.2023.09.2349","article-title":"Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)","volume":"34","author":"Schram","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104545_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104545_bib7","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jtho.2017.04.025","article-title":"Durable response to afatinib in lung adenocarcinoma harboring NRG1 gene fusions","volume":"12","author":"Gay","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104545_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2020-0379","article-title":"Therapeutic potential of afatinib in NRG1 fusion-driven solid tumors: a case series","volume":"26","author":"Cadranel","year":"2021","journal-title":"Oncologist"},{"issue":"15","key":"10.1016\/j.esmoop.2025.104545_bib9","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-19-0191","article-title":"NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","volume":"25","author":"Jones","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104545_bib10","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1093\/annonc\/mdx523","article-title":"Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer","volume":"28","author":"Jones","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104545_bib11","first-page":"399","article-title":"[Afatinib treatment for advanced mixed non-small cell lung cancer with CRISPLD2-NRG1 fusion: a case report and literature review]","volume":"27","author":"Chen","year":"2024","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"suppl","key":"10.1016\/j.esmoop.2025.104545_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JGO.2019.5.suppl.110","article-title":"Afatinib as a novel potential treatment option for NRG1 fusion-positive tumors","volume":"5","author":"Laskin","year":"2019","journal-title":"J Glob Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104545_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-023-03129-z","article-title":"Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report","volume":"21","author":"Nie","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.esmoop.2025.104545_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107469","article-title":"Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions","volume":"188","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104545_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00122","article-title":"Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","volume":"2018","author":"Mangat","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2025.104545_bib16","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1200\/JCO.23.00702","article-title":"Pembrolizumab in patients with tumors with high tumor mutational burden: results from the Targeted Agent and Profiling Utilization Registry Study","volume":"41","author":"Duvivier","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104545_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104545_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.esmoop.2025.104545_bib19","doi-asserted-by":"crossref","first-page":"iv80","DOI":"10.1093\/annonc\/mdz155.290","article-title":"NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option","volume":"30","author":"Weinberg","year":"2019","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925004144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925004144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:45:33Z","timestamp":1757576733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925004144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925004144"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104545","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Clinical Oncology, Inc. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104545"}}